Chronic Histologic Changes Are Present Regardless of HLA Mismatches: Evidence from HLA-Identical Living Donor Kidney Transplants.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
15
12
2020
medline:
1
4
2022
entrez:
14
12
2020
Statut:
ppublish
Résumé
At 5 and 10 y after kidney transplantation, chronic histologic changes such as arteriolar hyalinosis and mesangial expansion are common; however, determining cause is difficult. We compared surveillance biopsies in living donor kidney transplants (LDKTx) from HLA-matched siblings (termed HLA-identical [HLA-ID]) with HLA non-ID to investigate which histologic changes were likely due to alloimmune injury and which were due to nonalloimmune injury. We performed a retrospective, cohort study comparing HLA-ID sibling LDKTx (n = 175) with HLA non-ID LDKTx (n = 175; matched for age, sex, and year of transplant ±2 y) performed at a single institution from March 1999 to November 2018. Baseline characteristics and maintenance immunosuppression were similar. Mortality rates were similar, but in the HLA-ID group, 10-y death-censored graft survival was higher (93.8% versus 80.9% HLA non-ID LDKTx; P < 0.001), rejection rates were lower (after 1 y 9.6% versus 27.1%; P < 0.001), and Banff inflammation scores including glomerulitis and peritubular capillaritis were lower on surveillance biopsies at 1, 5, and 10 y. In contrast, chronic Banff scores (interstitial fibrosis, arteriolar hyalinosis, mesangial expansion, etc) were similar in prevalence and severity on surveillance biopsies at 1, 5, and 10 y. HLA-ID LDKTx have less inflammation and less transplant glomerulopathy, but most chronic histologic changes were similar to less well-matched LDKTx. We conclude that these types of chronic changes are not associated with HLA mismatches and may be due to nonimmunologic causes (hypertension, obesity, etc), suggesting that new management approaches to prevent these lesions may be needed.
Sections du résumé
BACKGROUND
At 5 and 10 y after kidney transplantation, chronic histologic changes such as arteriolar hyalinosis and mesangial expansion are common; however, determining cause is difficult. We compared surveillance biopsies in living donor kidney transplants (LDKTx) from HLA-matched siblings (termed HLA-identical [HLA-ID]) with HLA non-ID to investigate which histologic changes were likely due to alloimmune injury and which were due to nonalloimmune injury.
METHODS
We performed a retrospective, cohort study comparing HLA-ID sibling LDKTx (n = 175) with HLA non-ID LDKTx (n = 175; matched for age, sex, and year of transplant ±2 y) performed at a single institution from March 1999 to November 2018.
RESULTS
Baseline characteristics and maintenance immunosuppression were similar. Mortality rates were similar, but in the HLA-ID group, 10-y death-censored graft survival was higher (93.8% versus 80.9% HLA non-ID LDKTx; P < 0.001), rejection rates were lower (after 1 y 9.6% versus 27.1%; P < 0.001), and Banff inflammation scores including glomerulitis and peritubular capillaritis were lower on surveillance biopsies at 1, 5, and 10 y. In contrast, chronic Banff scores (interstitial fibrosis, arteriolar hyalinosis, mesangial expansion, etc) were similar in prevalence and severity on surveillance biopsies at 1, 5, and 10 y.
CONCLUSIONS
HLA-ID LDKTx have less inflammation and less transplant glomerulopathy, but most chronic histologic changes were similar to less well-matched LDKTx. We conclude that these types of chronic changes are not associated with HLA mismatches and may be due to nonimmunologic causes (hypertension, obesity, etc), suggesting that new management approaches to prevent these lesions may be needed.
Identifiants
pubmed: 33315759
pii: 00007890-202111000-00034
doi: 10.1097/TP.0000000000003579
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e244-e256Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Shi X, Lv J, Han W, et al. What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients. BMC Nephrol. 2018;19:116.
Yacoub R, Nadkarni GN, Cravedi P, et al. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney Int. 2018;93:482–490.
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016;374:940–950.
Chand S, Atkinson D, Collins C, et al. The spectrum of renal allograft failure. PLoS One. 2016;11:e0162278.
El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–535.
Gaston RS, Fieberg A, Helgeson ES, et al.; DeKAF Investigators*. Late graft loss after kidney transplantation: is “death with function” really death with a functioning allograft? Transplantation. 2020;104:1483–1490.
Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399.
Sellarés J, de Freitas DG, Mengel M, et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant. 2011;11:489–499.
Stegall MD, Gaston RS, Cosio FG, et al. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. J Am Soc Nephrol. 2015;26:20–29.
Van Loon E, Senev A, Lerut E, et al. Assessing the complex causes of kidney allograft loss. Transplantation. 2020;104:2557–2566.
Stegall MD, Cornell LD, Park WD, et al. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant. 2018;18:180–188.
Denic A, Morales MC, Park WD, et al. Using computer-assisted morphometrics of 5-year biopsies to identify biomarkers of late renal allograft loss. Am J Transplant. 2019;19:2846–2854.
Terasaki PI. The HLA-matching effect in different cohorts of kidney transplant recipients. Clinical Transpl. 2000:497–514.
Terasaki PI, Cho Y, Takemoto S, et al. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc. 1996;28:1144–1145.
de Mattos AM, Bennett WM, Barry JM, et al. HLA-identical sibling renal transplantation—a 21-yr single-center experience. Clin Transplant. 1999;13:158–167.
Leivestad T, Reisaeter AV, Brekke IB, et al. The role of HLA matching in renal transplantation: experience from one center. Rev Immunogenet. 1999;1:343–350.
Shimmura H, Tanabe K, Ishida H, et al. Long-term results of living kidney transplantation from HLA-identical sibling donors under calcineurin inhibitor immunosuppression. Int J Urol. 2006;13:502–508.
Lim WH, Gray NA, Chadban SJ, et al. Graft and patient outcomes of zero-human leucocyte-antigen-mismatched deceased and live donor kidney transplant recipients. Transpl Int. 2015;28:610–618.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18:293–307.
Bettinotti MP, Zachary AA, Leffell MS. Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant. 2016;21:453–458.
Schinstock CA, Gandhi MJ, Stegall MD. Interpreting anti-HLA antibody testing data: a practical guide for physicians. Transplantation. 2016;100:1619–1628.
Schinstock CA, Dadhania DM, Everly MJ, et al. Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study. Transpl Int. 2019;32:502–515.
Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90:68–74.
Lee YH, Lee JJ, Lee SY, et al. Long-term trends in the clinicopathologic features of kidney transplant recipients with graft dysfunction. Transplant Proc. 2019;51:3297–3303.
Naesens M, Kuypers DR, De Vusser K, et al. The histology of kidney transplant failure: a long-term follow-up study. Transplantation. 2014;98:427–435.
Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28:1912–1923.
Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf. 2015;14:1531–1546.
Lucan VC, Berardinelli L. Gastrointestinal side effects of post-transplant therapy. J Gastrointestin Liver Dis. 2016;25:367–373.
Baron PW, Infante S, Peters R, et al. Post-transplant diabetes mellitus after kidney transplant in Hispanics and Caucasians treated with tacrolimus-based immunosuppression. Ann Transplant. 2017;22:309–314.
Erturk T, Berber I, Cakir U. Effect of obesity on clinical outcomes of kidney transplant patients. Transplant Proc. 2019;51:1093–1095.
Pesce F, Martino M, Fiorentino M, et al. Recurrent urinary tract infections in kidney transplant recipients during the first-year influence long-term graft function: a single-center retrospective cohort study. J Nephrol. 2019;32:661–668.
Cohen JB, Lim MA, Tewksbury CM, et al. Bariatric surgery before and after kidney transplantation: long-term weight loss and allograft outcomes. Surg Obes Relat Dis. 2019;15:935–941.
Holdaas H, Jardine AG. BP targets in renal transplant recipients: too high or too low? J Am Soc Nephrol. 2014;25:1371–1373.
Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37–61.
Gill IS, Hodge EE, Novick AC, et al. Azathioprine vs cyclosporine in recipients of HLA-identical renal allografts. Cleve Clin J Med. 1994;61:206–210.
Verghese PS, Dunn TB, Chinnakotla S, et al. Calcineurin inhibitors in HLA-identical living related donor kidney transplantation. Nephrol Dial Transplant. 2014;29:209–218.
Venner JM, Famulski KS, Reeve J, et al. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1:e85323.
Gascó B, Revuelta I, Sánchez-Escuredo A, et al. Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation. Transplant Res. 2014;3:4.
Elias N, Cosimi AB, Kawai T. Clinical trials for induction of renal allograft tolerance. Curr Opin Organ Transplant. 2015;20:406–411.
Gallardo D, Brunet S, Torres A, et al. Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. Transplantation. 2004;77:1107–1110.
Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens. 2007;69:545–556.
Dragun D, Catar R, Philippe A. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int. 2016;90:280–288.
Farouk S, Zhang Z, Menon MC. Non-HLA donor-recipient mismatches in kidney transplantation—a stone left unturned. Am J Transplant. 2020;20:19–24.
Marino J, Paster J, Benichou G. Allorecognition by T lymphocytes and allograft rejection. Front Immunol. 2016;7:582.
Steers NJ, Li Y, Drace Z, et al. Genomic mismatch at LIMS1 locus and kidney allograft rejection. N Engl J Med. 2019;380:1918–1928.
Zhang Z, Menon MC, Zhang W, et al. Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosis. Kidney Int. 2020;98:758–768.
Ponticelli C. Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant. 2014;29:1134–1140.